LONDON (Reuters) – A controversial personal DNA testing kit from Google-backed genetics business 23andme was launched in Britain on Tuesday.
It offers users a chance to see if they are at risk from certain diseases and has a green light to go on sale, after securing a so-called “CE” mark of European quality assurance.
LONDON (Reuters) – GlaxoSmithKline will this week inform U.S. staff of hundreds of job cuts in its biggest market as the drugmaker starts implementing a major cost-saving program, sources familiar with the matter said on Sunday.
Britain’s top drugmaker announced at third-quarter results on Oct. 22 that the new restructuring scheme would save 1 billion pounds ($1.56 billion) in annual costs over three years, but it has yet to tell employees where the axe will fall.
LONDON (Reuters) – Merck KGaA (MRCG.DE: Quote, Profile, Research, Stock Buzz) aims to keep hold of its consumer healthcare unit, it said on Friday, pledging to develop a business that is expected to generate 2014 sales of $1 billion for the German drugs and chemicals company.
The non-prescription market has seen a wave of consolidation this year and a $17 billion deal for Merck to buy laboratory supplies business Sigma-Aldrich (SIAL.O: Quote, Profile, Research, Stock Buzz) has prompted some bankers to speculate it might consider selling the consumer unit.
FRANKFURT/LONDON (Reuters) – The Western world’s first gene therapy drug is set to go on sale in Germany with a 1.1 million euro ($1.4 million) price tag, a new record for a medicine to treat a rare disease.
The sky-high cost of Glybera, from Dutch biotech firm UniQure (QURE.O: Quote, Profile, Research, Stock Buzz) and its unlisted Italian marketing partner Chiesi, shows how single curative therapies to fix faulty genes may upend the conventional pharmaceutical business model.